Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ, has received FDA clearance for its Eovist MRI contrast agent.

Evoist is a gadolinium-based agent designed for use in imaging focal liver lesions.

Eovist is administered via an intravenous, bolus injection and has a dual route of excretion – approximately 50% via the liver and 50% via the kidney. The compound used in Evoist is gadoexetate disodium.